Using CRISPR/Cas9 to Correct Duchenne-Associated Dystrophin Deficiencies
CRISPR/Cas9, a revolutionary gene-editing tool, holds immense promise for correcting dystrophin deficiencies in Duchenne muscular dystrophy. By precisely targeting and modifying the DMD gene, CRISPR/Cas9 offers a potential therapeutic approach to restore dystrophin expression and alleviate the debilitating symptoms of this devastating disorder.